Amgen, Inc. (AMGN)
374.15
+12.82
(+3.55%)
USD |
NASDAQ |
Jul 02, 16:00
373.76
-0.39
(-0.10%)
After-Hours: 20:00
Amgen Price to Book Value : 21.97 for July 2, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| July 02, 2026 | 21.97 |
| July 01, 2026 | 21.22 |
| June 30, 2026 | 21.27 |
| June 29, 2026 | 21.17 |
| June 26, 2026 | 21.04 |
| June 25, 2026 | 20.72 |
| June 24, 2026 | 20.64 |
| June 23, 2026 | 20.38 |
| June 22, 2026 | 20.24 |
| June 18, 2026 | 19.83 |
| June 17, 2026 | 20.06 |
| June 16, 2026 | 20.43 |
| June 15, 2026 | 20.59 |
| June 12, 2026 | 20.86 |
| June 11, 2026 | 20.79 |
| June 10, 2026 | 19.83 |
| June 09, 2026 | 20.24 |
| June 08, 2026 | 20.30 |
| June 05, 2026 | 20.53 |
| June 04, 2026 | 20.30 |
| June 03, 2026 | 19.86 |
| June 02, 2026 | 19.28 |
| June 01, 2026 | 19.33 |
| May 29, 2026 | 19.78 |
| May 28, 2026 | 19.76 |
| Date | Value |
|---|---|
| May 27, 2026 | 19.74 |
| May 26, 2026 | 19.73 |
| May 22, 2026 | 19.93 |
| May 21, 2026 | 19.82 |
| May 20, 2026 | 19.47 |
| May 19, 2026 | 19.42 |
| May 18, 2026 | 19.05 |
| May 15, 2026 | 19.16 |
| May 14, 2026 | 19.75 |
| May 13, 2026 | 19.76 |
| May 12, 2026 | 19.75 |
| May 11, 2026 | 19.36 |
| May 08, 2026 | 19.48 |
| May 07, 2026 | 19.33 |
| May 06, 2026 | 19.45 |
| May 05, 2026 | 19.36 |
| May 04, 2026 | 19.02 |
| May 01, 2026 | 19.37 |
| April 30, 2026 | 20.33 |
| April 29, 2026 | 19.85 |
| April 28, 2026 | 19.94 |
| April 27, 2026 | 19.98 |
| April 24, 2026 | 20.23 |
| April 23, 2026 | 20.47 |
| April 22, 2026 | 20.31 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Biogen, Inc. | 1.710 |
| Gilead Sciences, Inc. | 6.933 |
| Regeneron Pharmaceuticals, Inc. | 2.186 |
| AbbVie, Inc. | -- |
| Viridian Therapeutics, Inc. | 3.944 |
Price to Book Value Related Metrics
| PE Ratio | 26.02 |
| PS Ratio | 5.441 |
| PEG Ratio | 0.8324 |
| Price to Free Cash Flow | 23.61 |
| Price | 374.15 |
| Earnings Yield | 3.84% |
| Market Cap | 201.93B |
| PEGY Ratio | 0.768 |
| Operating PE Ratio | 17.14 |
| Normalized PE Ratio | 23.50 |